Muscarinic Cholinergic Receptor Measurements with [18F]FP-TZTP: Control and Competition Studies
暂无分享,去创建一个
W C Eckelman | R E Carson | E Jagoda | P. Herscovitch | D. Kiesewetter | W. Eckelman | E. Jagoda | M. Der | M G Der | P Herscovitch | D O Kiesewetter | R. Carson
[1] E. Ginns,et al. Production of antisera selective for m1 muscarinic receptors using fusion proteins: distribution of m1 receptors in rat brain. , 1991, Molecular pharmacology.
[2] D. Kiesewetter,et al. Preparation of 18F-labeled muscarinic agonist with M2 selectivity. , 1995, Journal of medicinal chemistry.
[3] R. Reba,et al. Use of 3-quinuclidinyl 4-iodobenzilate as a receptor binding radiotracer. , 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[4] N. Elsayed,et al. Determination of physostigmine in plasma by high-performance liquid chromatography and fluorescence detection. , 1989, Analytical biochemistry.
[5] M M Mesulam,et al. Systematic regional differences in the cholinergic innervation of the primate cerebral cortex: Distribution of enzyme activities and some behavioral implications , 1986, Annals of neurology.
[6] R. Koeppe,et al. Synthesis, in vivo biodistribution and dosimetry of [11C]N-methylpiperidyl benzilate ([11C]NMPB), a muscarinic acetylcholine receptor antagonist. , 1995, Nuclear medicine and biology.
[7] David J. Schlyer,et al. Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[8] D. Mash,et al. Differential Regulation of Molecular Subtypes of Muscarinic Receptors in Alzheimer's Disease , 1995, Journal of neurochemistry.
[9] S. Gauthier,et al. Comparative Alterations of Nicotinic and Muscarinic Binding Sites in Alzheimer's and Parkinson's Diseases , 1992, Journal of neurochemistry.
[10] D E Kuhl,et al. Compartmental Analysis of [11C]Flumazenil Kinetics for the Estimation of Ligand Transport Rate and Receptor Distribution Using Positron Emission Tomography , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[11] S. Pappatà,et al. In vivo visualization of acetylcholinesterase with positron emission tomography. , 1993, Neuroreport.
[12] M. Durieux. Muscarinic Signaling in the Central Nervous System: Recent Developments and Anesthetic Implications , 1996, Anesthesiology.
[13] E. Hoffman,et al. Measuring PET scanner sensitivity: relating countrates to image signal-to-noise ratios using noise equivalents counts , 1990 .
[14] D E Kuhl,et al. [11C]Tropanyl Benzilate—Binding to Muscarinic Cholinergic Receptors: Methodology and Kinetic Modeling Alternatives , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[15] N. Volkow,et al. Age‐related decreases in muscarinic cholinergic receptor binding in the human brain measured with positron emission tomography (PET) , 1990, Journal of neuroscience research.
[16] E. Giacobini,et al. Cholinesterase inhibitor effects on extracellular acetylcholine in rat cortex , 1993, Neuropharmacology.
[17] A. Scremin,et al. Brain regional distribution of physostigmine and its relation to cerebral blood flow following intravenous administration in rats , 1990, Journal of neuroscience research.
[18] L. Farde,et al. Kinetic Analysis of Central [11C]Raclopride Binding to D2-Dopamine Receptors Studied by PET—A Comparison to the Equilibrium Analysis , 1989, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[19] M. Raichle,et al. Brain blood flow measured with intravenous H2(15)O. I. Theory and error analysis. , 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[20] F. Shishido,et al. Evaluation of Regional Differences of Tracer Appearance Time in Cerebral Tissues Using [15O]Water and Dynamic Positron Emission Tomography , 1988, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[21] A. Wellstein,et al. Distribution of m2 muscarinic receptors in rat brain using antisera selective for m2 receptors. , 1991, Molecular pharmacology.
[22] T G Turkington,et al. Performance characteristics of a whole-body PET scanner. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[23] F. Bymaster,et al. Novel Functional M1 Selective Muscarinic Agonists. Synthesis and Structure→Activity Relationships of 3‐(1,2,5‐Thiadiazolyl)‐1,2,5,6‐tetrahydro‐1‐methylpyridines. , 1992 .
[24] R. Hichwa,et al. In vivo Muscarinic Cholingeric Receptor Imaging in Human Brain with [11C]Scopolamine and Positron Emission Tomography , 1992 .
[25] D. Mash,et al. Distinct kinetic binding propeties of N‐[3H]‐methylscopolamine afford differential labeling and localization of M1, M2, and M3 muscarinic receptor subtypes in primate brain , 1993, Synapse.
[26] J S Ward,et al. Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines . , 1992, Journal of medicinal chemistry.
[27] M. Maziére. Cholinergic neurotransmission studied in vivo using positron emission tomography or single photon emission computerized tomography. , 1995, Pharmacology & therapeutics.
[28] A. Malhotra,et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[29] E. Giacobini,et al. Effects of cholinesterase inhibitors and clonidine coadministration on rat cortex neurotransmitters in vivo. , 1995, The Journal of pharmacology and experimental therapeutics.
[30] R. Hichwa,et al. In vivo muscarinic cholinergic receptor imaging in human brain with [11C]scopolamine and positron emission tomography. , 1992, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[31] W C Eckelman,et al. Quantification of Amphetamine-Induced Changes in [11C]Raclopride Binding with Continuous Infusion , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[32] R. Traystman,et al. Cerebral Blood Flow in Primates Is Increased by Isoflurane over Time and Is Decreased by Nitric Oxide Synthase Inhibition , 1994, Anesthesiology.
[33] Peter Herscovitch,et al. Journal of Cerebral Blood Flow and Metabolism Comparison of Bolus and Infusion Methods for Receptor Quantitation: Application to E8p]cyclofoxy and Positron Emission Tomography Cyclofoxy Infusion for Opiate Receptor Quant/tat/on Theory Compartment Models for Receptor-binding Radiotracers , 2022 .
[34] D J Brooks,et al. Comparison of Methods for Analysis of Clinical [11C]Raclopride Studies , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.